Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Theodore Mason

Otolaryngology Springfield, MA Medical Doctor

NPI 1619934668 CMS profile 345426

100 Wason Avenue, Suite 100, Springfield, MA 01107

Open in the dashboard

General payments

$3,825

36 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Theodore Mason of Springfield, MA is reported in the CMS Open Payments database as having received $3,825 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $476 4
2024 General $482 6
2023 General $442 7
2022 General $341 5
2020 General $147 1
2019 General $1,938 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Theodore Mason
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Theodore Mason were reported at $476. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Theodore Mason Otolaryngology median Middle half National median
2019 $1,938 $194 $82–$512 $163
2020 $147 $118 $42–$280 $114
2021 $0 $167 $63–$444 $132
2022 $341 $216 $84–$545 $149
2023 $442 $235 $93–$588 $160
2024 $482 $280 $111–$699 $164
2025 $476 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cochlear Americas $2,079 24 payments
  2. Cochlear Bone Anchored Solutions AB $1,431 3 payments
  3. Acclarent, Inc $113 5 payments
  4. MED-EL Corporation $101 1 payment
  5. Intersect ENT, Inc. $83 2 payments
  6. Sanofi-Aventis U.S. LLC $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,394 33 payments
  2. Consulting Fee $1,200 1 payment
  3. Travel and Lodging $231 2 payments
Products named General payments · program years 2019–2025
  1. Nucleus $1,914 8 payments
  2. Baha Implantable hearing solution $1,914 8 payments
  3. BAHA Implantable hearing solution $1,596 19 payments
  4. Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode $1,255 14 payments
  5. OSIA OSI300 IMPLANT $1,255 14 payments
  6. Cochlear Implantable hearing solution $341 5 payments
  7. Cochlear Implantable hearing solution $341 5 payments
  8. Osia $147 1 payment
  9. Mi1250 SYNCHRONY 2 FLEXsoft $101 1 payment
  10. BCI 602 Kit $101 1 payment
  11. Other $264 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

401

Median for Otolaryngology: 297

Drug cost

$9,705

Median for Otolaryngology: $6,314

Branded share of claims

35.4%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 29 $2,806
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 37 $1,907
Ofloxacin Generic 41 $1,512
Nortriptyline Hcl Generic 93 $1,013
Fluticasone Propionate Generic 53 $765
Ipratropium Bromide Generic 17 $650
Triamterene-Hydrochlorothiazid Triamterene/Hydrochlorothiazid Brand 36 $435
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 40 $288
Azelastine Hcl Generic 13 $231
Prednisone Generic 13 $51

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$159,076

Medicare's payments for the services billed

Medicare patients

931

Average age 73

Services billed

2,355

551 women, 380 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 48%
Depression 24%
Diabetes 21%
Ischemic heart disease 20%
Chronic kidney disease 20%
Osteoporosis 20%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record